A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.
Fung AS, Graham DM, Chen EX, Stockley TL, Zhang T, Le LW, Albaba H, Pisters KM, Bradbury PA, Trinkaus M, Chan M, Arif S, Zurawska U, Rothenstein J, Zawisza D, Effendi S, Gill S, Sawczak M, Law JH, Leighl NB.
Fung AS, et al. Among authors: zawisza d.
Lung Cancer. 2021 Jul;157:21-29. doi: 10.1016/j.lungcan.2021.05.021. Epub 2021 May 24.
Lung Cancer. 2021.
PMID: 34052705
Clinical Trial.